Free Trial

Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche

Alzheimer's blood test tube

Key Points

  • Investing in Alzheimer's treatment companies requires a balanced approach, weighing potential rewards against significant development and market risks.
  • Eli Lilly, Biogen, and Roche represent key players in this dynamic sector, each with distinct drug candidates, financial profiles, and competitive positions.
  • The Alzheimer's treatment landscape is complex and volatile, demanding comprehensive due diligence and a long-term investment perspective.
  • 5 stocks we like better than Eli Lilly and Company

The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that poses a significant and growing threat to global health and economic well-being. With an estimated 6.7 million Americans currently living with Alzheimer's and projected costs exceeding $2 trillion over the next decade, the urgency for effective treatments is undeniable. This unmet medical need has created an arena of intense research and development, attracting significant investment capital. 

The Pressing Need for Alzheimer's Therapies

Alzheimer's disease is characterized by a gradual decline in cognitive function, including memory loss, impaired judgment, and difficulty with language. As the disease progresses, individuals lose their ability to perform daily tasks, ultimately leading to complete dependence on caregivers. 

The profound impact of Alzheimer's extends far beyond the individual patient. Families face the emotional and financial strain of caring for loved ones while healthcare systems grapple with the escalating costs of long-term care. With the global prevalence of Alzheimer's expected to surge to 78 million by 2030, the demand for effective treatments is reaching a critical point. The development of disease-modifying therapies holds immense promise for improving patient outcomes and generating significant value for investors.

Eli Lilly and Company: Riding the Wave of Donanemab

Eli Lilly and Company NYSE: LLY is currently at the forefront of Alzheimer's treatment development, fueled by the promising results of their Donanemab clinical trials. Donanemab, a monoclonal antibody targeting amyloid plaques, showed a statistically significant slowing of cognitive decline in the Phase 3 TRAILBLAZER-ALZ 2 trial. This success, combined with the FDA's recent announcement to convene an advisory committee meeting in June 2024 to discuss Donanemab, has led Eli Lilly’s analyst community to predict a sizzling summer on the stock market for the company.


Eli Lilly and Company Today

Eli Lilly and Company stock logo
LLYLLY 90-day performance
Eli Lilly and Company
$848.90
-56.69 (-6.26%)
(As of 07/18/2024 ET)
52-Week Range
$446.56
$966.10
Dividend Yield
0.61%
P/E Ratio
125.02
Price Target
$858.72

Eli Lilly’s financials exhibit a solid picture of financial health. Eli Lilly’s earnings report for the first quarter of 2024 showcased a robust 26% revenue increase, demonstrating their ability to generate substantial cash flow. This financial strength underpins Eli Lilly's commitment to research and development, particularly in Alzheimer's disease. With a market capitalization exceeding $840 billion and a price-to-earnings (P/E) ratio hovering around 60, the company trades at an 11% premium, reflecting high investor expectations for future growth driven by Donanemab. However, potential investors should remain mindful of the inherent risks associated with clinical trials and regulatory approvals. While Donanemab holds immense promise, unforeseen complications or delays could significantly impact Eli Lilly’s stock price.

Eli Lilly and Company (LLY) Price Chart for Friday, July, 19, 2024

Biogen Inc.: Navigating Controversy and Charting a New Course

Biogen Inc. NASDAQ: BIIB has walked a troubled path in the Alzheimer's treatment arena. Their initial advance into the market, Aduhelm (aducanumab), garnered accelerated FDA approval in 2021 but faced significant criticism and limited market adoption due to concerns surrounding its efficacy, cost, and potential side effects. Biogen subsequently focused its efforts on Lecanemab, another amyloid-targeting antibody.

Biogen Today

Biogen Inc. stock logo
BIIBBIIB 90-day performance
Biogen
$225.25
-3.08 (-1.35%)
(As of 07/18/2024 ET)
52-Week Range
$189.44
$280.42
P/E Ratio
28.12
Price Target
$286.00

Lecanemab's recent traditional FDA approval, signaling a stronger clinical profile than its predecessor, has offered Biogen a chance at redemption. Early signs of market momentum are encouraging, with Biogen's earnings report for the first quarter of 2024 revealing a 2.5-fold increase in Lecanemab patients and a nearly threefold jump in global in-market sales. These positive developments have injected renewed confidence into Biogen's stock, which currently boasts a market capitalization of around $33 billion. However, the company's P/E ratio, hovering around 20, remains comparatively lower than Lilly's, suggesting Biogen’s analyst and investor community have a lingering degree of caution stemming from the Aduhelm controversy. Biogen's future success hinges on solidifying Lecanemab's market position and restoring investor trust.

Biogen Inc. (BIIB) Price Chart for Friday, July, 19, 2024

Roche Holding AG: Shifting Gears from Therapeutics to Diagnostics

Roche Holding AG OTCMKTS: RHHBY encountered a major setback in late 2022 when their amyloid-targeting drug, Gantenerumab, failed to meet primary endpoints in the Phase III GRADUATE trials. This disappointing outcome prompted Roche to re-evaluate its Alzheimer's treatment strategy, shifting its focus from therapeutics to diagnostics. Roche recently received FDA Breakthrough Device Designation for their Elecsys pTau217 plasma biomarker blood test, designed to aid in earlier Alzheimer's diagnosis.

Roche Today

Roche Holding AG stock logo
RHHBYRHHBY 90-day performance
Roche
$39.34
+0.34 (+0.87%)
(As of 07/18/2024 ET)
52-Week Range
$29.20
$39.92
Dividend Yield
2.16%
Price Target
$40.00

With a market capitalization exceeding $230 billion and a P/E ratio of around 20, Roche remains a financially stable and diversified pharmaceutical sector giant. While the setback with Gantenerumab has dampened investor enthusiasm for their Alzheimer's treatment prospects, their diagnostic pivot presents a new avenue for growth. If successful, the Elecsys pTau217 blood test could be critical in facilitating early intervention and potentially pave the way for more effective treatment strategies.

Roche Holding AG (RHHBY) Price Chart for Friday, July, 19, 2024

The Complexities of Alzheimer's Drug Development

Investing in companies pursuing Alzheimer's treatments requires understanding the risks and challenges. Clinical trials for Alzheimer's drugs are notoriously complex and have a high failure rate. The multifactorial nature of the disease, the difficulty in measuring cognitive decline, and the ethical considerations of enrolling vulnerable patients all contribute to the complexity of these trials. Regulatory approval is also a formidable hurdle. The FDA's standards for demonstrating safety and efficacy are rigorous, and the agency has been exceptionally cautious in evaluating new Alzheimer's drugs, given the history of disappointments and controversies.

Even with FDA approval, market adoption and commercial success are not guaranteed. The potential for unforeseen side effects, the high cost of treatment, and the limited access to specialized diagnostic tools can all impede market penetration. Furthermore, the emergence of generic drugs or biosimilars could erode market share for successful treatments in the future. Investors must carefully weigh these risks against the potential rewards when investing in this volatile sector.

Financial Considerations and Competitive Dynamics

Financial analysis that extends beyond recent quarterly earnings is essential when evaluating investment opportunities in the Alzheimer's treatment market. Investors should consider a company's long-term financial health, including revenue diversification, profitability, debt levels, and research and development expenditures. Analyst estimates and projections for future revenue growth provide valuable insights into the potential market size for successful treatments.

Eli Lilly and Company benefits from diversified revenue streams, including leading products in diabetes, oncology, and immunology, providing a stable financial foundation. Their strong profitability, manageable debt levels, and commitment to research and development position them well for future growth, particularly if Donanemab achieves market success. However, they compete with other companies that are developing amyloid-targeting therapies, such as Biogen with Lecanemab.

Biogen relies more heavily on its multiple sclerosis franchise, making it more susceptible to setbacks in Alzheimer's drug development. While Lecanemab's recent FDA approval has provided a boost, its long-term success is not guaranteed. The Aduhelm controversy has impacted Biogen's profitability, and the company carries a higher debt load than Eli Lilly. Analyst estimates for Biogen's future revenue growth are more conservative, reflecting its challenges in re-establishing investor confidence and securing Lecanemab's market share.

Roche is a diversified pharmaceutical giant, and the company enjoys a broad revenue base across various therapeutic areas, minimizing the impact of any single product. Roche’s financial performance is characterized by high profitability and low debt levels, providing a solid foundation for exploring new opportunities, such as their recent pivot towards Alzheimer's diagnostics. However, this market's revenue potential remains less defined than therapeutics. Roche must also navigate a competitive landscape that includes Lilly, Biogen, and many smaller biotech companies focused on various aspects of Alzheimer's disease.

Evaluating Investment Opportunities in Alzheimer’s Treatment

Investing in the Alzheimer's treatment market is a calculated gamble. The potential rewards are immense, driven by the vast unmet medical need and the promise of groundbreaking therapies that could transform millions of lives. However, the path to success is filled with obstacles and uncertainties, demanding a cautious and discerning approach from investors.

Alzheimer's drug clinical trials are complex and have high failure rates. Regulatory approvals are stringent, and even with FDA clearance, market adoption and commercial success are not guaranteed. The competitive landscape is fierce, with multiple companies vying for market share in a rapidly evolving field.

Investors seeking to capitalize on the potential of Alzheimer's treatments must carefully weigh the risks and rewards. A comprehensive due diligence process is essential, encompassing a thorough analysis of each company's financial health, drug development pipeline, and competitive positioning. Understanding the science behind the therapies, the complexities of clinical trials, and the dynamics of regulatory approval is crucial for making informed investment decisions.

Setbacks and disappointments are common, and volatility is inherent. However, for those willing to embrace calculated risks, the Alzheimer's treatment market offers a compelling opportunity to contribute to a meaningful cause while potentially reaping significant financial returns. The key lies in balancing optimism with a healthy dose of realism and making investment choices grounded in sound analysis and a long-term perspective.

The Future of Alzheimer’s Treatment: Promises and Realities for Investors

The search for effective Alzheimer's treatments represents one of the most significant scientific and medical challenges of our time. For investors, this dynamic field offers both immense promise and considerable risk. These three companies are at the forefront of this endeavor, each bringing their own strengths, strategies, and challenges to the table. While the road to success is paved with uncertainties, the potential for groundbreaking discoveries and significant returns for investors makes the Alzheimer's treatment sector a compelling area to watch. Continued research, development, and investment are crucial to advancing the fight against Alzheimer's disease and ultimately transforming the lives of millions affected by this devastating disorder.

Should you invest $1,000 in Eli Lilly and Company right now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report
Jeffrey Neal Johnson
About The Author

Jeffrey Neal Johnson

Contributing Author

Retail and Technology Stocks

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Eli Lilly and Company (LLY)
4.8641 of 5 stars
4.86 / 5 stars
$848.90-6.3%0.61%125.02Moderate Buy$858.72
Biogen (BIIB)
4.9552 of 5 stars
4.96 / 5 stars
$225.25-1.3%N/A28.12Moderate Buy$286.00
Roche (RHHBY)
0.7562 of 5 stars
0.76 / 5 stars
$39.34+0.9%2.16%N/AReduce$40.00
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

3 Top Market Leaders Splitting Their Stocks
How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines